46,089 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Purchased by Proficio Capital Partners LLC

Proficio Capital Partners LLC acquired a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 46,089 shares of the company’s stock, valued at approximately $443,000.

Other large investors also recently added to or reduced their stakes in the company. M&T Bank Corp bought a new stake in MiMedx Group during the 4th quarter valued at $368,000. Cornerstone Investment Partners LLC bought a new stake in shares of MiMedx Group in the fourth quarter valued at about $210,000. Phocas Financial Corp. purchased a new stake in MiMedx Group in the fourth quarter worth about $306,000. Bank of New York Mellon Corp grew its holdings in MiMedx Group by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in MiMedx Group by 93.0% during the 4th quarter. New York State Common Retirement Fund now owns 57,840 shares of the company’s stock worth $556,000 after acquiring an additional 27,867 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Trading Up 2.0 %

MDXG opened at $8.10 on Tuesday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.97. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The stock has a fifty day moving average price of $8.36 and a 200-day moving average price of $7.88.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Transactions at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now directly owns 440,178 shares in the company, valued at $3,473,004.42. The trade was a 11.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock valued at $1,130,312 in the last 90 days. Insiders own 1.30% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.